tbuckley/cabot-search huggingface dataset:
Prescription Drugs in Paperback
Authors: E.J. H.
Journal: Annals of Internal Medicine (1971)

Letters and Comments1 January 1971Prescription Drugs in PaperbackE.J. H.E.J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-74-1-148_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOur recent review of Dr. Richard Burack's The New Handbook of Prescription Drugs (p. 498, September 1970) commented that its most important audience is students and house officers. More of them would be reached, noted the reviewer, with a cheaper paperback edition than with the relatively costly hardback edition supplied to us as the review copy.We have heard from Ballantine Books, Inc., that they are publishing a paperback edition. It sells for $1.25. At this price—lower than that for two issues ofPlayboy—no medical student has an excuse for not owning Burack's incomparable guide to more effective and less... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1971Volume 74, Issue 1Page: 148-148KeywordsDrugs ePublished: 1 December 2008 Issue Published: 1 January 1971 PDF downloadLoading ...
Ebb Tide
Authors: Richard Bronson
Journal: Annals of Internal Medicine (2015)

Ad Libitum7 April 2015Ebb TideRichard Bronson, MDRichard Bronson, MDFrom Stony Brook, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-0112 Audio Reading - “Ebb Tide” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Ebb Tide," by R. Bronson. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Little by littlethey drifted into dream,left behindtheir world of joys and sorrows,family, friends,entered an inner life.We tried to call them backthrough music, verse,and momentarily,they looked around,smiled at familiar faces,stamped their feetto the beat of a remembered tune—when they had danced with a wife,taken a husband by the hand.The crueltyfor those left behind—who could not follow themto wherever they went,could not knowthe inner lives of their secret worldsfrom which there would be no waking.Richard Bronson, MDStony Brook, New York Author, Article, and Disclosure InformationAffiliations: From Stony Brook, New York.Current Author Address: Richard Bronson, MD; e-mail, Richard.[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Ebb Tide” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Ebb Tide," by R. Bronson. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 7 April 2015Volume 162, Issue 7Page: 525 ePublished: 7 April 2015 Issue Published: 7 April 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
WOODBURY VS. EDDY.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Open Access Change
Authors: Stephanie Winkelbeiner, Philipp Homan, Ramesh Raghavan
Journal: JAMA Psychiatry (2020)

Jazz Croft, MSc; Jon Heron, PhD; Christoph Teufel, PhD; Mary Cannon, PhD; Dieter Wolke, PhD; Andrew Thompson, PhD; Lotte Houtepen, PhD; Stanley Zammit, PhD
New therapeutic approaches for hemoglobinopathies: Pharmacologic agents impacting pathophysiology
Authors: Miguel R. Abboud
Journal: HemaSphere (2018)

American University of Beirut Medical Center (AUBMC), Beirut, Lebanon This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
Miscellany
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Routines
Authors: Caroline E. Wellbery
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Angiotensin II antagonism blunts cardiac MCP-1 expression and macrophage infiltration in an animal model of evolving heart failure Thomas M. Behr, Sandhya S. Nerurkar, Frank C. Barone, Robert N. Willette, Allen H. Nelson, Christiane E. Angermann, Karin M. Anderson, Robert W. Coatney, Eliot H. Ohlstein, Jonathan D. Sackner-Bernstein. SmithKline Beecham Pharmacology, King of Prussia, PA, St. Luke's Roosevelt Hospital, New York, NY
Journal: Journal of the American College of Cardiology (2001)
Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes.
Journal: BMJ (1986)

A collaborative study of screening programmes in eight countries was performed to estimate the risks of cervical cancer associated with different screening policies. Most of the data came from centrally organised screening programmes. Relative protection was higher in women who had had two or more negative results of screening tests than in those who had had only one negative smear, particularly in the first five years after the last test. There was little difference in the protection afforded by screening every year compared with every three years, but screening only once every five or 10 years offered appreciably less protection. The age of the women did not affect the sensitivity of the test or the sojourn time of the disease (the length of the detectable preclinical phase during which abnormal cytology could be picked up if a smear were taken); invasive cancer in women under 25 was rare. Centrally organised screening programmes were more effective than uncoordinated screening. Screening programmes should be aimed principally at women aged 35-60 but should start some years before the age of 35, and the intervals between screening should be three years or less.
Uremic Stomatitis
Authors: Mishaal Talish, Ashley M. DiLorenzo
Journal: New England Journal of Medicine (2020)

A 26-year-old man with chronic kidney disease presented with white, sharply demarcated, adherent plaques on the tongue. The blood urea nitrogen level was more than 225 mg per deciliter. The appearance was consistent with uremic stomatitis, and hemodialysis was initiated.
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
Authors: Hiroshige Yoshioka, Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka
Journal: Journal of Clinical Oncology (2014)

8117 Background: WJTOG3405 has proven that chemotherapy-naïve patients with postoperative recurrent or stage IIIB/IV NSCLC harboring activating EGFRmutation have longer progression free survival (PFS) when treating with G than treating with CD. (9.2 months (mos.) for G vs. 6.3 mos. for CD, hazard ratio (HR) 0.489, 95% confidence interval (CI): 0.336-0.710). (Mitsudomi et al., Lancet Oncol. 2010) Although we reported updated overall survival results of this study after 34 mos. median follow-up period, the impact on overall survival (OS) was still unclear because of lack of survival events. (Mitsudomi et al, ASCO 2012). Methods: Overall survival (OS) was re-evaluated using updated data (data cutoff, 30 Sep, 2013, median follow-up, 59.1 mos.) for 172 patients. Results: One hundred twenty-seven events had occurred (73.8%). Median survival time (MST) for G arm was 34.8 mos. (95% CI: 26.0 – 39.5) which was not significantly different from 37.3 mos. (95% CI: 31.2 – 45.5) for CD arm (HR 1.252, 95% CI 0.883-1.775). Multivariate analysis using Cox proportional hazards model revealed that postoperative recurrence or IIIB/IV significantly affected OS among assessed covariates (treatment arm, smoking status, sex, age, postoperative recurrence or IIIB/IV, and mutation type). The overall survival of patients with postoperative recurrence was better than that of those with IIIB/IV stage disease (HR 0.459, 95% CI 0.312-0.673, p < 0.001). In the CD arm, 8 patients (9%) never received EGFR-TKI in their whole courses of therapy, whereas 31 patients (36%) never received chemotherapy in the G arm. MST for the former and the latter group were 13.5 months (95% CI: 6.5 -) and 44.5 months (95% CI: 21.3 - 51.8), respectively. Conclusions: This five-year follow-up OS analysis confirmed that G for advanced NSCLC with EGFR mutation offers survival benefit of 3 years. There was no difference in OS whether the initial treatment was G or CD, probably due to high cross over rate. Clinical trial information: 000000539.
ON FAeCAL FERMENTATION AS A SOURCE OF DISEASE
Authors: C. H. F. Routh
Journal: BMJ (1856)

attacking that and other forms of constitutional ulcer, and running its devastating course almost without let or hin- drance.Several very marked cases of this kind of ulcer have been in Guy's and St. Bartholomew's Hospitals re- cently, but yieldinig more readily to opiate treatment than to any other which had been tried.Joseph R., aged 53, admitted into Guy's Hospital, Aug. 13th,with what has subsequently proved to be a large phagedsenic spreading sore of penis and scrotum-one of those cases, according to Mr. COCK, under whose care the case has been treated, which would do better in the country than in the confined air and inferior hygienic conditions of a crowded hospital like Guy's.The poor man has lost flesh, and become quite haggard looking and old, or, as he ex- presse it himself, " he is twenty years older looking this month than last"-the constitutional effect has been so iu- tense and continuous.On his first admission to hospital, Mr. Cock essayed to bring the ulcer under the influence of chlorate of potash, but was disappointed, as he states he
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents
Authors: David Klein
Journal: American Journal of Psychiatry (2006)

Objective: Second-generation, or atypical, antipsychotics effectively treat psychiatric illness in children and adolescents. However, weight gain and abnormalities in insulin sensitivity, including diabetes, complicate this therapy. Method: A 16-week double-blind, placebo-controlled trial was conducted to evaluate the effectiveness of metformin in managing weight gain in 39 subjects, ages 10–17, whose weight had increased by more than 10% during less than 1 year of olanzapine, risperidone, or quetiapine therapy. Body weight, body mass index (kilograms per square meter of height), and waist circumference were measured regularly, as were fasting insulin and glucose levels. Results: Weight was stabilized in subjects receiving metformin, while those receiving placebo continued to gain weight (0.31 kg/week). Because the study was conducted with growing children, metformin treatment resulted in reduction in z scores for both weight and body mass index. The homeostasis model assessment, a surrogate indicator of insulin sensitivity, decreased in treated subjects. Overt diabetes was diagnosed in two subjects before treatment (elevated baseline fasting glucose and insulin values) and in two placebo-treated subjects (one at week 12 and the other after study completion). One subject taking placebo developed impaired fasting glucose. Placebo treatment was associated with the need to perform oral glucose tolerance testing upon study completion, by which three additional subjects were identified with impaired glucose tolerance. No serious adverse events resulted from metformin treatment. Conclusions: Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals.
EARLY MEDICAL HISTORY.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bihormonal theory of diabetes gets solid backing
Authors: C. Macek
Journal: JAMA (1982)

Researchers at the University of Arizona, Tucson, have discovered evidence to support the "bihormonal" theory of diabetes—that the disease is caused by an excess of glucagon as well as a deficiency of insulin. Professor of chemistry Victor J. Hruby, PhD, working with Marvin D. Bregman, PhD, and Dev Trivedi, MS, produced an analog of glucagon ([1-Nα-trinitrophenylhistidine, 12-homoarginine] glucagon, or THG) by altering the side groups of two amino acids on the hormone. The resulting THG is a potent antagonist of the glucagon-stimulated adenylate cyclase system in rat liver. It presumably works by reversibly binding to glucagon receptors on liver cells, competing successfully with glucagon and thereby preventing glycogenolysis (and release of glucose) in the liver. The substance was tested for its ability to lower blood glucose concentrations in diabetic rats by David G. Johnson, MD, associate professor of pharmacology, and Camy Ulichny Goebel, of the Department of Internal Medicine at
Manual of General Medicinal Technology, Including Prescription Writing.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Eosinophilic Esophagitis
Authors: Hiroaki Kusunose, Shuichi Ohara
Journal: New England Journal of Medicine (2007)

Eosinophilic esophagitis (EoE) is a clinicopathologic condition of increasing recognition and prevalence. Because of elevated total IgE levels and high rates of concurrent allergic diseases compared with the general population, EoE appears to be an antigen-driven immunologic process that caused by allergens like food or aeroallergens. EoE is a disease that features dense intraepithelial infiltration by eosinophils which cause excessive mucosal immunologic reactions which cause several symptoms that mostly involve dysphagia. For establishment of the diagnosis, infiltration of eosinophils (≥ 20 eosinophils/HPF) should be identified in an esophageal mucosal biopsy specimen. In treatment of patients have a possibility of EoE, proton-pump inhibitors(PPIs) must be tried as first choice. Other proved therapeutic options include topical or systemic corticosteroids, chronic dietary elimination, and esophageal dilation, but local administration of glucocorticoids has recently been reported as useful therapy for EoE.
Effects of angiotensin II receptor blockade on fibrinolysis and coagulation in patients with acute myocardial infarction Hirofumi Soejima, Hisao Ogawa, Keiji Takazoe, Shinzo Miyamoto, Ichiro Kajiwara, Hideki Shimomura. Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto City, Japan
Journal: Journal of the American College of Cardiology (2001)
Zentralblatt für Neurochirurgie, Leipzig
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: F<scp>ifty</scp> Y<scp>ears</scp> <scp>of</scp> R<scp>esearch</scp> <scp>in</scp> ARDS. Setting Positive End-Expiratory Pressure in Acute Respiratory Distress Syndrome
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Definition of abbreviations: CI = confidence interval; HR = hazard ratio; N/A = not applicable: HR could not be calculated because the assessment was made only at 6 yr of age; OR = odds ratio.Treatment effects adjusted for gestational age, smokers in the home, and a family history of allergy.